Retatrutide calculator

This is a research reference, not a product for sale or a dosing recommendation. No amount is selected for Retatrutide. A listed name does not mean it is supplied in a vial or should be injected.

About Retatrutide

Retatrutide, also called LY3437943, is an investigational single peptide designed to activate GIP, GLP-1, and glucagon receptors. This three-receptor profile is being studied for metabolic effects, including changes in body weight and glycemic measures. A randomized Phase 2 obesity trial provides human research data, but its results do not establish approval, long-term outcomes, or how the compound compares with approved therapies across different populations.

At a glance

Class: Investigational triple agonist of the GIP, GLP-1, and glucagon receptors.
Studied mechanism: The molecule is designed to combine incretin-receptor activity with glucagon-receptor activity; the contribution of each pathway to observed effects remains under study.
Evidence context: A placebo-controlled Phase 2 obesity trial reported human outcomes; this is earlier-stage evidence and does not make retatrutide an approved drug.

Blank arithmetic calculator

For independently verified inputs, concentration equals entered vial amount in mg divided by added liquid in mL. Entered requested mg divided by concentration gives mL; multiplying mL by the actual syringe markings per mL gives units. Enable JavaScript to use the calculator. This math does not establish that a compound is suitable for injection.

Common questions

Which receptors does retatrutide target?

It is designed to activate the GIP, GLP-1, and glucagon receptors, hence its description as a triple agonist.

Does a Phase 2 trial establish retatrutide as an approved treatment?

No. Phase 2 findings are clinical research evidence, not regulatory approval; efficacy, safety, and longer-term outcomes require further study.

Research & references

Related compound pages

Read the math guides · Browse all compound names